Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma

Results of the Phase III RELEVANCE trial (NCT01476787) of rituximab-lenalidomide for untreated follicular lymphoma were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. Nathan Fowler, MD, of the MD Anderson Cancer Center, Houston, TX, discusses these results and their importance here.